Alembic Pharma Q2 FY27 Consolidated Revenue at ₹2,603 Crore, Profit at ₹335 Crore
Alembic Pharmaceuticals reported strong Q2 FY27 results. Consolidated revenue rose to ₹2,603.48 crore, and profit after tax was ₹335.17 crore. Standalone revenue was ₹2,391.65 crore with profit after tax at ₹409.36 crore. EPS improved significantly for both consolidated and standalone figures.
The substantial increase in revenue and profit, coupled with improved EPS, indicates a strong financial performance which is likely to have a significant positive impact on investor sentiment and the company's stock.
The company reported significant year-on-year growth in both revenue and profit for the quarter and half-year ended September 30, 2026, across both consolidated and standalone financial results, indicating strong business performance.
Alembic Pharmaceuticals Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors approved the consolidated and standalone financial results.
For the quarter ended September 30, 2026, the consolidated revenue from operations stood at ₹2,603.48 crore, a notable increase from ₹1,910.15 crore in the same quarter last year. Consolidated profit after tax attributable to owners of the company was ₹335.17 crore, compared to ₹184.71 crore in the prior year's corresponding quarter. Earnings per share (EPS) for the quarter stood at ₹17.05, up from ₹9.40 in Q2 FY26.
On a standalone basis, revenue from operations for the quarter was ₹2,391.65 crore, up from ₹1,796.24 crore in Q2 FY26. Standalone profit after tax for the quarter was ₹409.36 crore, an increase from ₹179.36 crore in the previous year. Standalone EPS was ₹20.83 compared to ₹9.12 in Q2 FY26.
The company's consolidated debt-equity ratio was reported at 0.25 times as of September 30, 2026, and the net worth stood at ₹5,936.60 crore. The auditors' report was unqualified.
What to do with a filing like this
Alembic Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alembic Pharmaceuticals Limited. Read the original for the full detail.